Merck Reports Strong Q1 2026 Earnings, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy MRK?
Source: Yahoo Finance
- Significant Revenue Growth: Merck's Q1 2026 revenue reached $16.29 billion, reflecting a 4.9% year-on-year increase that surpassed analyst expectations of $15.82 billion, indicating robust performance in oncology and animal health sectors.
- Improved Adjusted EPS: The company reported an adjusted loss of $1.28 per share, which was 13.2% better than the consensus estimate of $1.47, showcasing management's confidence in new product launches and rising market demand.
- New Product Launches Drive Growth: Merck introduced IDVYNSO for HIV and NUMELVI for canine allergic dermatitis, signaling ongoing efforts to expand its product portfolio and market reach, which are expected to fuel future revenue growth.
- Strategic Investments and Restructuring: Merck plans to increase commercial and R&D spending to support new product launches while reorganizing its commercial operations to enhance execution, with expectations that these initiatives will create long-term value over the next decade.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 112.300
Low
95.00
Averages
119.53
High
139.00
Current: 112.300
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Merck Unveils Novel Oral PCSK9 Inhibitor Enlicitide
- Drug Development Progress: Merck announced the publication of a scalable synthesis method for its novel oral PCSK9 inhibitor, Enlicitide, in the journal Science, showcasing its potential to be the first approved oral PCSK9 inhibitor, thereby providing new treatment options for cardiovascular disease patients.
- Biocatalysis Technology Application: The study details the biocatalytic assembly of Enlicitide using a suite of enzymes, significantly enhancing synthesis efficiency and demonstrating Merck's technical prowess in biocatalysis, which could transform traditional drug synthesis methods and promote sustainability in the pharmaceutical industry.
- Market Demand Response: Enlicitide is designed to lower LDL-C levels by inhibiting interactions with LDL receptors, addressing the growing global demand for cardiovascular disease treatments, especially as cardiovascular-related mortality continues to rise, highlighting its significant market implications.
- Strategic Investment and Commitment: With over 25 years of investment in biocatalysis, Merck is dedicated to developing novel enzymes and manufacturing processes, reflecting the company's long-term commitment to innovative drug development aimed at improving global patient health outcomes.
See More
Equity Markets Steady Amid Uncertainty; Quality Dividend Stocks Attract Investors
- Market Performance: The S&P 500 has risen 7% year-to-date, demonstrating resilience amid economic uncertainty and geopolitical instability, although fresh challenges may still arise in the future.
- Amgen's Outlook: Despite facing biosimilar competition, Amgen is expected to see revenue growth in 2026, supported by a diverse product lineup and a strong pipeline, with 16 brands achieving double-digit growth in Q1.
- Merck's Strategy: Merck's key drug Keytruda will lose patent protection in 2028, but the approval of a subcutaneous version is expected to retain patients, while new drugs like Winrevair and Capvaxive are performing well in the market.
- Dividend Appeal: Both Amgen and Merck offer around a 3% dividend yield, significantly higher than the S&P 500's average of 1.1%, and both companies have notably increased their dividends over the past decade, attracting income-seeking investors.
See More
Doceree Launches New System for Pharma Brand Teams
- Collaboration of Industry Leaders: Doceree's Daily Command system, co-built by 75 senior operators including 18 leaders from firms like Sanofi and Merck, signifies a fundamental shift in how pharmaceutical brand teams operate, enhancing decision-making efficiency and transparency.
- Workflow Transformation: Daily Command integrates strategies, creative, and measurement frameworks into a single platform, enabling brand teams to access and manage their work in real-time, significantly improving operational efficiency and team collaboration.
- Market Competitive Advantage: In an environment where pharmaceutical marketing budgets are under sustained pressure, agencies adopting Daily Command will be able to showcase their strategic recommendations within brand teams' daily decision-making processes, thereby increasing client retention and ensuring a competitive edge in the future.
- Open Ecosystem: The Daily Command marketplace allows agencies to integrate their proprietary tools and measurement frameworks directly into the system, ensuring that agencies' intellectual property and data partnerships remain intact, thus fostering innovation and collaboration.
See More
Eli Lilly's Mounjaro Becomes World's Best-Selling Drug
- Sales Surge: Eli Lilly's Mounjaro achieved $8.66 billion in Q1 2026 sales, a 126% increase from $3.84 billion a year ago, surpassing Merck's Keytruda to become the world's top-selling drug, significantly boosting the company's profits.
- International Market Expansion: Mounjaro generated $4.2 billion in U.S. sales, up 59%, while international sales skyrocketed from $1.2 billion to $4.4 billion, primarily due to its inclusion in China's National Reimbursement Drug List, indicating strong global growth potential.
- New Drug Launch: The U.S. launch of Foundayo, an anti-obesity pill, has attracted over 20,000 patients and received prescriptions from more than 8,000 physicians, expected to further drive revenue growth amid a large global obesity population.
- Optimistic Future Outlook: Eli Lilly anticipates total revenue of $84.4 billion in 2026, nearing $100 billion by 2027, with strong sales from Mounjaro and Zepbound, positioning the company favorably for investors looking for growth opportunities.
See More
Analyst Raises Merck Price Target to $112 After Q1 Beat
- Q1 Performance Beat: Merck reported Q1 sales of $8 billion on April 30, exceeding expectations of $7.6 billion, primarily driven by a 12% increase in sales of its cancer immunotherapy Keytruda, highlighting strong market demand.
- Price Target Increase: Morgan Stanley analyst Terence Flynn raised Merck's price target from $109 to $112 while maintaining an 'Equal Weight' rating, reflecting confidence in the company's growth trajectory following the earnings beat.
- Guidance Adjustment: Merck narrowed its 2026 profit guidance to a range of $5.04 to $5.16 per share, with sales expectations between $65.8 billion and $67 billion, indicating a positive outlook for future performance.
- Investment Potential Analysis: While Merck is viewed as a promising investment, Morgan Stanley suggests that certain AI stocks may offer greater upside potential and lower downside risk, urging investors to consider their options carefully.
See More
Salesforce and Merck Collaborate on Unified Customer Platform
- Customer Platform Integration: Salesforce collaborates with Merck Animal Health to build a 360° customer platform using OneCRM, integrating devices, prescriptions, and customer information into a single system, thereby enhancing service convenience and efficiency.
- Enhanced Online Services: The platform is expected to improve Merck Animal Health's online services and customer support, leading to increased customer growth and retention, thereby strengthening market competitiveness.
- Cost and Efficiency Optimization: By leveraging better sales and automation, the system is anticipated to reduce operational costs and improve efficiency, supporting margin growth and enhancing the company's financial health.
- Strategic Collaboration Significance: This partnership not only highlights Salesforce's potential expansion in the healthcare sector but also underscores Merck's commitment to digital transformation, aiming to enhance overall business performance through technological innovation.
See More
Merck Unveils Novel Oral PCSK9 Inhibitor Enlicitide
- Drug Development Progress: Merck announced the publication of a scalable synthesis method for its novel oral PCSK9 inhibitor, Enlicitide, in the journal Science, showcasing its potential to be the first approved oral PCSK9 inhibitor, thereby providing new treatment options for cardiovascular disease patients.
- Biocatalysis Technology Application: The study details the biocatalytic assembly of Enlicitide using a suite of enzymes, significantly enhancing synthesis efficiency and demonstrating Merck's technical prowess in biocatalysis, which could transform traditional drug synthesis methods and promote sustainability in the pharmaceutical industry.
- Market Demand Response: Enlicitide is designed to lower LDL-C levels by inhibiting interactions with LDL receptors, addressing the growing global demand for cardiovascular disease treatments, especially as cardiovascular-related mortality continues to rise, highlighting its significant market implications.
- Strategic Investment and Commitment: With over 25 years of investment in biocatalysis, Merck is dedicated to developing novel enzymes and manufacturing processes, reflecting the company's long-term commitment to innovative drug development aimed at improving global patient health outcomes.
See More
Equity Markets Steady Amid Uncertainty; Quality Dividend Stocks Attract Investors
- Market Performance: The S&P 500 has risen 7% year-to-date, demonstrating resilience amid economic uncertainty and geopolitical instability, although fresh challenges may still arise in the future.
- Amgen's Outlook: Despite facing biosimilar competition, Amgen is expected to see revenue growth in 2026, supported by a diverse product lineup and a strong pipeline, with 16 brands achieving double-digit growth in Q1.
- Merck's Strategy: Merck's key drug Keytruda will lose patent protection in 2028, but the approval of a subcutaneous version is expected to retain patients, while new drugs like Winrevair and Capvaxive are performing well in the market.
- Dividend Appeal: Both Amgen and Merck offer around a 3% dividend yield, significantly higher than the S&P 500's average of 1.1%, and both companies have notably increased their dividends over the past decade, attracting income-seeking investors.
See More
Doceree Launches New System for Pharma Brand Teams
- Collaboration of Industry Leaders: Doceree's Daily Command system, co-built by 75 senior operators including 18 leaders from firms like Sanofi and Merck, signifies a fundamental shift in how pharmaceutical brand teams operate, enhancing decision-making efficiency and transparency.
- Workflow Transformation: Daily Command integrates strategies, creative, and measurement frameworks into a single platform, enabling brand teams to access and manage their work in real-time, significantly improving operational efficiency and team collaboration.
- Market Competitive Advantage: In an environment where pharmaceutical marketing budgets are under sustained pressure, agencies adopting Daily Command will be able to showcase their strategic recommendations within brand teams' daily decision-making processes, thereby increasing client retention and ensuring a competitive edge in the future.
- Open Ecosystem: The Daily Command marketplace allows agencies to integrate their proprietary tools and measurement frameworks directly into the system, ensuring that agencies' intellectual property and data partnerships remain intact, thus fostering innovation and collaboration.
See More
Eli Lilly's Mounjaro Becomes World's Best-Selling Drug
- Sales Surge: Eli Lilly's Mounjaro achieved $8.66 billion in Q1 2026 sales, a 126% increase from $3.84 billion a year ago, surpassing Merck's Keytruda to become the world's top-selling drug, significantly boosting the company's profits.
- International Market Expansion: Mounjaro generated $4.2 billion in U.S. sales, up 59%, while international sales skyrocketed from $1.2 billion to $4.4 billion, primarily due to its inclusion in China's National Reimbursement Drug List, indicating strong global growth potential.
- New Drug Launch: The U.S. launch of Foundayo, an anti-obesity pill, has attracted over 20,000 patients and received prescriptions from more than 8,000 physicians, expected to further drive revenue growth amid a large global obesity population.
- Optimistic Future Outlook: Eli Lilly anticipates total revenue of $84.4 billion in 2026, nearing $100 billion by 2027, with strong sales from Mounjaro and Zepbound, positioning the company favorably for investors looking for growth opportunities.
See More
Analyst Raises Merck Price Target to $112 After Q1 Beat
- Q1 Performance Beat: Merck reported Q1 sales of $8 billion on April 30, exceeding expectations of $7.6 billion, primarily driven by a 12% increase in sales of its cancer immunotherapy Keytruda, highlighting strong market demand.
- Price Target Increase: Morgan Stanley analyst Terence Flynn raised Merck's price target from $109 to $112 while maintaining an 'Equal Weight' rating, reflecting confidence in the company's growth trajectory following the earnings beat.
- Guidance Adjustment: Merck narrowed its 2026 profit guidance to a range of $5.04 to $5.16 per share, with sales expectations between $65.8 billion and $67 billion, indicating a positive outlook for future performance.
- Investment Potential Analysis: While Merck is viewed as a promising investment, Morgan Stanley suggests that certain AI stocks may offer greater upside potential and lower downside risk, urging investors to consider their options carefully.
See More
Salesforce and Merck Collaborate on Unified Customer Platform
- Customer Platform Integration: Salesforce collaborates with Merck Animal Health to build a 360° customer platform using OneCRM, integrating devices, prescriptions, and customer information into a single system, thereby enhancing service convenience and efficiency.
- Enhanced Online Services: The platform is expected to improve Merck Animal Health's online services and customer support, leading to increased customer growth and retention, thereby strengthening market competitiveness.
- Cost and Efficiency Optimization: By leveraging better sales and automation, the system is anticipated to reduce operational costs and improve efficiency, supporting margin growth and enhancing the company's financial health.
- Strategic Collaboration Significance: This partnership not only highlights Salesforce's potential expansion in the healthcare sector but also underscores Merck's commitment to digital transformation, aiming to enhance overall business performance through technological innovation.
See More
